Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-10-16 12:40:06 UTC |
---|
Update Date | 2022-03-07 02:49:25 UTC |
---|
HMDB ID | HMDB0005010 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Sertraline |
---|
Description | Sertraline is a selective serotonin uptake inhibitor that is used in the treatment of depression. Sertraline hydrochloride (also labeled under numerous brand names: Zoloft, Sertralin, Lustral, Apo-Sertral, Asentra, Gladem, Serlift, Stimuloton, Xydep, Serlain, Concorz) is an orally administered antidepressant of the selective serotonin reuptake inhibitor (SSRI) type. It was first approved by the Food and Drug Administration (FDA) in 1991. Sertraline is an odorless, white, sparingly soluble crystalline solid. The minimum effective dose is usually 50 mg per day (it can be still effective at 25 mg or 37.5 mg), but lower doses may be used in the initial weeks of treatment to acclimate the patient's body, especially the liver, to the drug and to minimize the severity of any side effects. Patients who do not experience relief of symptoms at 50 mg a day may have their dose increased, up to 200 mg a day. Sertraline (HCl) is used medically mainly to treat the symptoms of depression and anxiety. It is also prescribed for the treatment of obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), panic disorder (PD) and social phobia/social anxiety disorder. A study has shown that sertraline is an effective treatment for impulsive aggressive behavior in personality disordered patients. |
---|
Structure | CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12 InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(+)-Sertraline | ChEBI | (1S,4S)-Sertraline | ChEBI | (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine | ChEBI | cis-(+)-Sertraline | ChEBI | CP 51974 | ChEBI | Sertralina | ChEBI | Sertralinum | ChEBI | Sertraline hydrochloride | HMDB | Zoloft | HMDB | Besitran | HMDB | Gen sertraline | HMDB | Novo sertraline | HMDB | Parke davis brand OF sertraline hydrochloride | HMDB | Ratiopharm brand OF sertraline hydrochloride | HMDB | Rhoxal sertraline | HMDB | Sertraline hydrochloride (1S-cis)-isomer | HMDB | Altruline | HMDB | Lustral | HMDB | Novo-sertraline | HMDB | Rhoxalpharma brand OF sertraline hydrochloride | HMDB | Roerig brand OF sertraline hydrochloride | HMDB | Sealdin | HMDB | Ratio sertraline | HMDB | Ratio-sertraline | HMDB | Apo sertraline | HMDB | Apo-sertraline | HMDB | Aremis | HMDB | Boehringer ingelheim brand OF sertraline hydrochloride | HMDB | Gladem | HMDB | Pfizer brand OF sertraline hydrochloride | HMDB | Apotex brand OF sertraline hydrochloride | HMDB | Esteve brand OF sertraline hydrochloride | HMDB | Gen-sertraline | HMDB | Genpharm brand OF sertraline hydrochloride | HMDB | Hydrochloride, sertraline | HMDB | Lacer brand OF sertraline hydrochloride | HMDB | Novopharm brand OF sertraline hydrochloride | HMDB | Rhoxal-sertraline | HMDB |
|
---|
Chemical Formula | C17H17Cl2N |
---|
Average Molecular Weight | 306.23 |
---|
Monoisotopic Molecular Weight | 305.073804963 |
---|
IUPAC Name | (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine |
---|
Traditional Name | sertraline |
---|
CAS Registry Number | 79617-96-2 |
---|
SMILES | CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12 |
---|
InChI Identifier | InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1 |
---|
InChI Key | VGKDLMBJGBXTGI-SJCJKPOMSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tametralines. Tametralines are compounds containing a tametraline moiety, which consists of a tetrahydronaphthalene linked to a phenyl group to form N-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Tetralins |
---|
Sub Class | Tametralines |
---|
Direct Parent | Tametralines |
---|
Alternative Parents | |
---|
Substituents | - Tametraline
- 1,2-dichlorobenzene
- Chlorobenzene
- Halobenzene
- Aralkylamine
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Secondary aliphatic amine
- Secondary amine
- Organohalogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic nitrogen compound
- Amine
- Organochloride
- Organonitrogen compound
- Aromatic homopolycyclic compound
|
---|
Molecular Framework | Aromatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredictor | Adduct Type | CCS Value (Å2) | Reference |
---|
DeepCCS | [M-2H]- | 202.253 | 30932474 | DeepCCS | [M+Na]+ | 177.48 | 30932474 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Sertraline,1TMS,isomer #1 | CN([C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21)[Si](C)(C)C | 2486.2 | Semi standard non polar | 33892256 | Sertraline,1TMS,isomer #1 | CN([C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21)[Si](C)(C)C | 2706.2 | Standard non polar | 33892256 | Sertraline,1TMS,isomer #1 | CN([C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21)[Si](C)(C)C | 2942.5 | Standard polar | 33892256 | Sertraline,1TBDMS,isomer #1 | CN([C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21)[Si](C)(C)C(C)(C)C | 2676.2 | Semi standard non polar | 33892256 | Sertraline,1TBDMS,isomer #1 | CN([C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21)[Si](C)(C)C(C)(C)C | 2993.0 | Standard non polar | 33892256 | Sertraline,1TBDMS,isomer #1 | CN([C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C21)[Si](C)(C)C(C)(C)C | 3063.5 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Sertraline GC-MS (Non-derivatized) - 70eV, Positive | splash10-004j-0490000000-724d07a27d5e8d538495 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Sertraline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-00b9-2890000000-d53a90b04ec8457ad2f1 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline LC-ESI-QTOF , positive-QTOF | splash10-004i-0091000000-10f81c7fd0a8c096039d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline LC-ESI-QTOF , positive-QTOF | splash10-056r-0980000000-58873180fd0c95a215b3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline LC-ESI-QTOF , positive-QTOF | splash10-0bt9-0900000000-35c397f9293e114f3234 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline LC-ESI-QTOF , positive-QTOF | splash10-0a4i-0900000000-569e7b0694b3ef81cf90 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline , positive-QTOF | splash10-056r-0970000000-2de49c544ebd922028dc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline , positive-QTOF | splash10-056r-0970000000-7753c869949091f5c066 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline , positive-QTOF | splash10-056r-0970000000-a995c3f140efa6578777 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline , positive-QTOF | splash10-0bt9-2900000000-dee4675a5062129266c9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline LC-ESI-QFT , positive-QTOF | splash10-0a6r-0950000000-2a9cba59b69c41b10a59 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 35V, Positive-QTOF | splash10-0a6r-0950000000-c83a31b55267aefe212a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 40V, Positive-QTOF | splash10-0a4i-0900000000-dd599a43cebe678e826d | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 50V, Positive-QTOF | splash10-0a4i-0900000000-f3cbee6abbbc3ca370b4 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 10V, Positive-QTOF | splash10-004i-0290000000-c5202d63a9c4b21b0775 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 20V, Positive-QTOF | splash10-0a4i-0910000000-565998e1b2eefa1c2ccb | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 40V, Positive-QTOF | splash10-0a4i-0900000000-fef875b785017dd6bb4f | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 30V, Positive-QTOF | splash10-0bt9-0900000000-1c524b8999874349f051 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 40V, Positive-QTOF | splash10-0a4i-0900000000-bf056f6f75a4ccc5d4c9 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 20V, Positive-QTOF | splash10-056r-0980000000-58873180fd0c95a215b3 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sertraline 10V, Positive-QTOF | splash10-004i-0091000000-10f81c7fd0a8c096039d | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sertraline 10V, Positive-QTOF | splash10-0a4i-0139000000-4f4b68d5ff5484e81ce9 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sertraline 20V, Positive-QTOF | splash10-0a4i-1779000000-742a47a4d5d21cc8acb1 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sertraline 40V, Positive-QTOF | splash10-03xr-1960000000-f03bdc5054705000574c | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sertraline 10V, Negative-QTOF | splash10-0udi-0009000000-d658426c80474367477a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sertraline 20V, Negative-QTOF | splash10-0udi-0029000000-68fb5194b39f7a3d992b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sertraline 40V, Negative-QTOF | splash10-0kwo-4390000000-925d4346a5a2a057e466 | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Membrane (predicted from logP)
|
---|
Biospecimen Locations | |
---|
Tissue Locations | - Brain
- Liver
- Placenta
- Platelet
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.15 (0.00032-0.32) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB01104 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023583 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 61881 |
---|
KEGG Compound ID | C07246 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Sertraline |
---|
METLIN ID | 2417 |
---|
PubChem Compound | 68617 |
---|
PDB ID | SRE |
---|
ChEBI ID | 9123 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Corey, E. J.; Gant, Thomas G. A catalytic enantioselective synthetic route to the important antidepressant sertraline. Tetrahedron Letters (1994), 35(30), 5373-6. |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
- Agnel M, Esnaud H, Langer SZ, Graham D: Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter. Biochem Pharmacol. 1996 May 3;51(9):1145-51. [PubMed:8645336 ]
- Serebruany VL, Suckow RF, Cooper TB, O'Connor CM, Malinin AI, Krishnan KR, van Zyl LT, Lekht V, Glassman AH: Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry. 2005 Jun;162(6):1165-70. [PubMed:15932816 ]
- Parsey RV, Kent JM, Oquendo MA, Richards MC, Pratap M, Cooper TB, Arango V, Mann JJ: Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry. 2006 May 1;59(9):821-8. Epub 2005 Oct 6. [PubMed:16213473 ]
- Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC: Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry. 2000 Jun;157(6):1006-8. [PubMed:10831484 ]
- Epperson CN, Jatlow PI, Czarkowski K, Anderson GM: Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. Pediatrics. 2003 Nov;112(5):e425. [PubMed:14595087 ]
- Serebruany VL, Gurbel PA, O'Connor CM: Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001 May;43(5):453-62. [PubMed:11394937 ]
- Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y: The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol. 1995 Nov;40(5):481-5. [PubMed:8703653 ]
- Phillips OM, Wood KM, Williams DC: Kinetics of the interaction of sertraline with the human platelet plasma membrane 5-hydroxytryptamine carrier. Eur J Pharmacol. 1988 Feb 9;146(2-3):299-306. [PubMed:3371401 ]
- Pivac N, Muck-Seler D, Sagud M, Jakovljevic M, Mustapic M, Mihaljevic-Peles A: Long-term sertraline treatment and peripheral biochemical markers in female depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):759-65. [PubMed:12921906 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
---|